Financial Health Check: Examining BioXcel Therapeutics Inc (BTAI)’s Key Ratios

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

BioXcel Therapeutics Inc (NASDAQ: BTAI) closed the day trading at $2.06 down -3.29% from the previous closing price of $2.13. In other words, the price has decreased by -$3.29 from its previous closing price. On the day, 0.73 million shares were traded. BTAI stock price reached its highest trading level at $2.23 during the session, while it also had its lowest trading level at $2.06.


For a better understanding of BTAI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.57.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.

On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 ’24 when Mehta Vimal sold 5,268 shares for $2.62 per share. The transaction valued at 13,823 led to the insider holds 43,564 shares of the business.

Steinhart Richard I sold 1,069 shares of BTAI for $2,817 on Apr 04 ’24. The Chief Financial Officer now owns 4,765 shares after completing the transaction at $2.63 per share. On Apr 04 ’24, another insider, Yocca Frank, who serves as the Chief Scientific Officer of the company, sold 1,067 shares for $2.63 each. As a result, the insider received 2,812 and left with 12,763 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 77313448 and an Enterprise Value of 105508488. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.93. Its current Enterprise Value per Revenue stands at 60.085 whereas that against EBITDA is -0.752.

Stock Price History:

The Beta on a monthly basis for BTAI is 0.39, which has changed by -0.9223521 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $28.46, while it has fallen to a 52-week low of $1.91. The 50-Day Moving Average of the stock is -23.16%, while the 200-Day Moving Average is calculated to be -39.46%.

Shares Statistics:

Over the past 3-months, BTAI traded about 746.55K shares per day on average, while over the past 10 days, BTAI traded about 541150 shares per day. A total of 29.93M shares are outstanding, with a floating share count of 28.34M. Insiders hold about 24.48% of the company’s shares, while institutions hold 25.98% stake in the company. Shares short for BTAI as of 1714435200 were 1502004 with a Short Ratio of 2.01, compared to 1711584000 on 2491144. Therefore, it implies a Short% of Shares Outstanding of 1502004 and a Short% of Float of 5.37.

Most Popular

[the_ad id="945"]